Portfolio News
Sofinnova Crossover
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
• Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026
• Cash runway guidance remains unchanged from July 30, 20262
• Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026
• Key highlights from the first half of 2026 and recent Company updates
• Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results
Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.
To read the full press release please visit the Inventiva website.
Related News
IMIO Raises $12M from Sofinnova Partners and Chipotle's Cultivate Next to Scale Reliable Biologicals and Improve Soil Performance
TIME Names Recor Medical’s Paradise Ultrasound Renal Denervation System one of the Best Inventions of 2026
COAPTIUM® CONNECT Named One of TIME’s Best Inventions of 2026
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
Sitryx Reports Positive Phase 1b Results for First-in-Class Oral PKM2 Modulator SYX-5219 in Patients with Moderate to Severe Atopic Dermatitis